Center for Scientific Review; Amended Notice of Meeting, 29165 [06-4673]
Download as PDF
<![CDATA[
Federal Register / Vol. 71, No. 97 / Friday, May 19, 2006 / Notices
known as Emt and Tsk) and the
resulting decrease in HIV infectivity,
replication, and transcription for
exemplary purposes. Importantly,
inhibition of Itk expression does not
affect the expression of HIV receptors
CCR5, CXCR4, or CD4. The current
technology could be used in
combination with therapeutics that
target multiple stages of the virus life
cycle.
This research is described, in part, in
the following:
1. D Dombroski, R Houghtling, CM
Labno, J Burkhardt, and PL
Schwartzberg, ‘‘Kinase-independent
functions for Itk in the regulation of Vav
and the actin cytoskeleton,’’ J. Immunol.
174: 1385–1392, 2005.
2. A Takesono, R Horai, M Mandai, D
Dombroski, and PL Schwartzberg,
‘‘Requirement for Tec family kinases in
chemokine-induced migration and
activation of Cdc42 and Rac,’’ Curr.
Biol. 10:917–22, 2004.
3. E Schaeffer, G Yap, CM Lewis, M
Czar, DW McVicar, AW Cheever, A
Sher, and PL Schwartzberg, ‘‘Mutation
of Tec family kinases alters T helper cell
differentiation,’’ Nature Immunol.
2:1183–8, 2001.
In addition to licensing, the
technology is available for further
development through collaborative
research opportunities with the
inventors: The NHGRI, Genetic Disease
Research Branch/Cell Signalling
Section, is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize the use of Tec family
kinase inhibitors as a therapeutic target
for HIV and other viral infections.
Please contact Claire Driscoll, Director,
NHGRI Technology Transfer Office, at
301/402–2537 or cdriscol@mail.nih for
more information.
wwhite on PROD1PC61 with NOTICES
Peptide Inhibitors of HIV–1 Integrase
Useful for the Treatment of Retroviral
Infection and HIV
Peter P. Roller et al. (NCI)
U.S. Provisional Application No. 60/
534,378 filed 06 Jan 2004 (HHS
Reference No. E–039–2004/0–US–01).
U.S. Provisional Application No. 60/
547,067 filed 25 Feb 2004 (HHS
Reference No. E–039–2004/1–-US–
01).
U.S. Provisional Application No. 60/
599,856 filed 10 Aug 2004 (HHS
Reference No. E–039–2004/2–US–01).
PCT Application No. PCT/US2004/
42726 filed 21 Dec 2004 (HHS
Reference No. E–039–2004/3–PCT–
01), which published as WO 2005/
068492 on 29 Dec 2005.
VerDate Aug<31>2005
17:37 May 18, 2006
Jkt 208001
29165
Licensing Contact: Sally Hu, Ph.D.,
M.B.A.; 301/435–5606;
hus@mail.nih.gov.
The invention describes the discovery
of short peptides, derived from the
natural peptide named indolicidin that
have an ability to inhibit HIV–1
integrase and exhibit antiviral activity.
In particular, this invention shows that
synthesized derivatives of the
indolicidin peptides named RIN–25
exhibit a significant higher anti-viral
and anti-integrase activity when
compared to the parent compound
named RIN–42. HIV–1 integrase has a
good potential of being the next
therapeutic target since HIV–1 integrase
is essential for viral replication and
there is no cellular equivalent. Thus,
subject invention may be used in the
development of therapeutics for the
treatment of retroviral infections, such
as AIDS, or other retroviral-related
diseases (i.e., cancer, immune
disorders). In addition, the novel
peptides described in this invention
may also have particular value when
used in combination treatments with
other antiviral therapies directed at
other viral targets, such as protease and
reverse transcriptase.
pharmaceutical composition, such as a
therapeutic or prophylactic product,
that modulates antigen presenting cell
activity, comprising contacting an APC
with a candidate ligand which interacts
with the APC, analyzing the activation
state of the APC; and selecting ligands
that activate a killer T cell in the
absence of a helper T cells as the
candidates for incorporation into the
pharmaceutical. Also claimed are
related methods where the ligand
interacts with CD40 or where the APC
is a dendritic cell. The embodiments
have several applications in the field of
immunology, and enable to manufacture
novel pharmaceuticals and vaccine
components for the treatment and
prevention of cancer, systemic infection,
and autoimmune responses.
The technology is further described in
JP Ridge, F Di Rosa, and P Matzinger,
‘‘A conditioned dendritic cell can be a
temporal bridge between a CD4+ Thelper and a T-killer cell,’’ Nature 1998
Jun 4; 393(6684):474–8.
In addition to licensing, the
technology is available for further
development through collaborative
research opportunities with the
inventors.
Identification of Candidate Ligands
which Modulate Antigen Presenting
Cells
Dated: May 11, 2006.
David R. Sadowski,
Acting Director, Division of Technology
Development and Transfer, Office of
Technology Transfer, National Institutes of
Health.
[FR Doc. E6–7627 Filed 5–18–06; 8:45 am]
Polly Matzinger, John P. Ridge (NIAID).
U.S. Patent No. 6,680,176 issued 20 Jan
2004 (HHS Reference No. E–055–
1999/0–US–01).
Licensing Contact: Cristina
Thalhammer-Reyero; 301/435–4507;
thalhamc@mail.nih.gov.
Available for licensing and
commercial development are novel
biotechnological tools, prophylactics,
therapeutics, and methods for
modulating the activation state of an
antigen presenting cell (APC) and
thereby modulating the activation of a
killer T cell. The activation of a killer
T cell can occur in a two cell complex
and two sequential steps: (a) In the first
step, an APC stimulates a T helper T
cell, which in turn stimulates or
‘‘superactivates’’ the APC to
differentiate to a state where it can
independently stimulate a killer T cell;
(b) In the second step, the APC
encounters the killer T cell and
stimulates it so that killer T cell priming
is achieved in a helper independent
fashion. The first step can be bypassed
altogether by viral infection or an
interaction with certain molecules at the
cell surface of APCs, such as CD40.
More specifically, the invention consists
of a method of identifying a ligand as a
candidate for incorporation into a
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the Center for Scientific
Review Special Emphasis Panel, June
13, 2006, 3 p.m. to June 13, 2006, 4:30
p.m., National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
which was published in the Federal
Register on May 5, 2006, 71 FR 26550–
26552.
The meeting will be held on June 15,
2006. The meeting time and location
remain the same. The meeting is closed
to the public.
Dated: May 11, 2006.
Anna Snouffer,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 06–4673 Filed 5–18–06; 8:45 am]
BILLING CODE 4140–01–M
E:\FR\FM\19MYN1.SGM
19MYN1
]]>Agencies
[Federal Register Volume 71, Number 97 (Friday, May 19, 2006)]
[Notices]
[Page 29165]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 06-4673]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Amended Notice of Meeting
Notice is hereby given of a change in the meeting of the Center for
Scientific Review Special Emphasis Panel, June 13, 2006, 3 p.m. to June
13, 2006, 4:30 p.m., National Institutes of Health, 6701 Rockledge
Drive, Bethesda, MD 20892 which was published in the Federal Register
on May 5, 2006, 71 FR 26550-26552.
The meeting will be held on June 15, 2006. The meeting time and
location remain the same. The meeting is closed to the public.
Dated: May 11, 2006.
Anna Snouffer,
Acting Director, Office of Federal Advisory Committee Policy.
[FR Doc. 06-4673 Filed 5-18-06; 8:45 am]
BILLING CODE 4140-01-M
